API | lutetium (177Lu) vipivotide tetraxetan

lutetium (177Lu) vipivotide tetraxetan (Pluvicto) Report issue

Small molecule Approved ^FDA First in Class Breakthrough Therapy ^FDA Priority Review ^FDA

AACT

Active Ingredient History

NOW

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: 1216.07
ALogP: Missing data
ChEMBL Molecule:
lutetium lu 177 vipivotide tetraxetan

More Chemistry

Pharmacology

Mechanisms of Action:
- Glutamate carboxypeptidase 2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Payload: 177Lu
Black Box: No
Availability: Prescription Only
Delivery Methods: Parenteral
Pro Drug: No

177lu-psma-617 | lu177-psma-617

Organizations (42)

Research & Development (42)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (10)

Approved Indications (2)

Prostatic Neoplasms (approved 2022)

Prostatic Neoplasms, Castration-Resistant

Experimental Indications - Clinical Trial Phases 1-4 (10)

Carcinoma, Adenoid Cystic (Early Phase 1)

Castration (Phase 1)

Drugs, Investigational (Phase 2)

Genital Neoplasms, Male (Phase 2)

Neoplasms (Phase 2)

Neoplasms by Site (Phase 2)

Prostatic Diseases (Phase 2)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Urogenital Neoplasms (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 40
# of Trial Organizations: 42

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue